Axelera AI Secures up to €61.6 Million Grant to Develop Scalable AI Chiplet for High-Performance Computing
As part of the DARE consortium, Axelera AI will support the EuroHPC JU and its effort to develop a World Class Supercomputing Ecosystem in Europe. DARE aims to foster the design and development of European processors, accelerators, and related technologies for extreme-scale, high-performance, and emerging applications.
'Our D-IMC technology leverages a future-proof, scalable multi-AI-core architecture, ensuring unparalleled adaptability and efficiency. Enhanced with proprietary RISC-V vector extensions, this versatile mixed-precision platform is engineered to excel across diverse AI workloads,' explained Evangelos Eleftheriou, CTO and co-founder of Axelera AI. 'Uniquely, our architecture facilitates scaling from the edge to the cloud, streamlining expansion and optimizing performance in ways that traditional cloud-to-edge approaches cannot. We are setting a new standard for AI infrastructure, making true scalability a tangible reality.'
Why it matters: The AI market is growing at 28%+ CAGR with the vast majority of that expansion driven by inference. However, existing concerns around performance, cost, efficiency and sustainability of cloud-based solutions are intensifying due to industry advancements. Innovations such as reasoning models (i.e. OpenAI -o1 and DeepSeek R1) require significantly more inference computing than earlier transformer models. Targeting a deployment date of 2028, Axelera AI's Titania is engineered to address these challenges by delivering superior throughput and efficiency for data-intensive AI applications and future zetta-scale HPC centers at a competitive price.
To support this development effort, Axelera will grow its research and development teams in the Netherlands, Italy and Belgium.
How it works: The Titania chiplet-based architecture will leverage the company's unique D-IMC technology along with RISC-V capabilities, to meet the increasing AI demands across various market sectors, including HPC, enterprise data centers, robotics, automotive, and others, while maintaining the efficiency of an edge-oriented architecture. Leveraging D-IMC allows for near-linear scalability in performance without the significant power and cooling overhead typical of other solutions. Integrating RISC-V technology with vector extensions enables Axelera AI to rapidly innovate in response to evolving customer needs. Multiple Titania chiplets will be packaged in a System-in-Package (SiP).
'This is an important milestone and validation of our technology. Since Axelera AI was founded in July 2021, we have continuously delivered technologies to help customers tackle the AI industry's biggest challenges and efficiently implement AI capabilities into their products,' said Fabrizio Del Maffeo, Co-Founder and CEO at Axelera AI. 'Today, we deliver a cutting-edge hardware and software platform for accelerating computer vision on edge devices at a fraction of the cost and energy consumption of current solutions. Titania builds upon this unique product suite. We're grateful to the EuroHPC DARE Project and the countries involved for helping accelerate the development of this groundbreaking AI inference technology for HPC data centers.'
The EuroHPC JU was established to develop, deploy, extend and maintain an integrated world-class supercomputing and quantum computing infrastructure to foster and support a highly competitive and innovative HPC ecosystem. Axelera AI's Titania technology is ideal for building extremely scalable, energy-efficient and highly resilient HPC and data center technologies.
'I am proud to announce the launch of the DARE project which marks a significant milestone for European digital sovereignty,' said Anders Jensen, EuroHPC JU Executive Director. 'This ambitious initiative will drive innovation in both hardware and software technologies and leverage the full power of HPC and AI to develop secure, efficient and European-led solutions for the future.'
The development of Titania aligns with Axelera AI's mission to democratize AI and complements the company's current product offerings. This includes the Metis™ AI Platform that simplifies the development, integration and deployment of AI inference acceleration and achieves a 3-5x increase in efficiency and performance. To learn more about current and future product offerings from the edge to the data center to address the growing computing needs for generative AI, large language models and large multi-modal models, visit Axelera.ai.
Accelerate your innovation now with the Metis AI, available for ordering.
Axelera AI is the leading provider of purpose-built AI hardware acceleration technology for AI inference, including computer vision and generative AI applications. Its first-generation product is the game-changing Metis™ AI platform – a holistic hardware and software solution for Edge AI inference which delivers the world's highest performance and energy-efficiency at a fraction of the cost of alternative solutions. Headquartered in the AI Innovation Center of the High Tech Campus in Eindhoven, The Netherlands, Axelera AI has R&D offices in Belgium, Switzerland, Italy and the UK, with more than 200 employees across three continents. Its team of experts in AI software and hardware hail from top AI firms and Fortune 500 companies.
SOURCE: Axelera AI
Copyright Business Wire 2025.
PUB: 03/06/2025 05:00 AM/DISC: 03/06/2025 05:02 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
Lead-Free Piezoelectric Ceramics Market to Grow 12.3% Annually Through 2030
"Driven by Rising Environmental Regulations and Breakthrough R&D, Lead-Free Piezoelectric Ceramics Emerge as a Key Enabler of Sustainable Electronics Innovation" BOSTON, Aug. 20, 2025 /PRNewswire/ -- According to the latest study from BCC Research, the "Lead-Free Piezoelectric Ceramics: Technologies and Global Opportunities" is projected to grow from $307.3 million in 2025 to $549.8 million by the end of 2030, at a compound annual growth rate (CAGR) of 12.3% from 2025 through 2030. This report presents a comprehensive analysis of the global market for lead-free piezoelectric ceramics, offering qualitative and quantitative insights. The market is segmented by material, including potassium sodium niobate (KNN), bismuth sodium titanate (BNT), barium titanate (BT), and others. It is also categorized by configuration, such as monolith, multilayer, and thin films, and by end users, including consumer electronics and optoelectronics, transportation, industrial equipment, medical, and others. Regional analysis covers Asia-Pacific (China, Japan, South Korea, and the rest of APAC), Europe (Germany, France, Italy, and the rest of Europe), North America (U.S., Canada, and Mexico), and the Rest of the World (RoW). RoW includes South America, and the Middle East, and Africa. This report is especially relevant now due to growing global concerns over the health and environmental risks associated with lead, a key component in traditional PZT piezoelectric materials. As awareness of these risks increases, industries and researchers are actively seeking eco-friendly alternatives. Additionally, stricter regulations under frameworks like REACH and ROHS are accelerating the shift toward lead-free technologies. These regulatory pressures, particularly in the European Union, are expected to gradually phase out lead-based materials in specific applications, making the development and adoption of lead-free piezoelectric ceramics a timely and critical focus. The factors driving the market's growth include: Adverse Health and Ecological Impacts of Lead-Based Piezoelectric Materials: Due to lead toxicity, lead-based ceramics pose serious health risks and environmental hazards. Exposure can lead to neurological and developmental issues, while improper disposal contaminates ecosystems. These dangers are pushing industries to adopt safer, lead-free alternatives. Favorable Regulatory Environment: Global regulations like the EU's RoHS and WEEE directives restrict the use of hazardous substances, including lead, in electronics. These policies encourage manufacturers to shift toward environmentally friendly materials, creating a supportive market for lead-free piezoelectric ceramics. Increasing Applications for Lead-Free Piezoelectric Ceramics: Advances in material science have expanded the use of lead-free ceramics across sectors such as consumer electronics, healthcare, automotive, and industrial automation. Their growing versatility and safety make these materials a preferred choice for modern applications. Request a sample copy of the global market for lead-free piezoelectric ceramics report. Report Synopsis Report Metric Details Base year considered 2024 Forecast period considered 2025-2030 Base year market size $279.0 million Market size forecast $549.8 million Growth rate CAGR of 12.3% from 2025 to 2030 Segments covered Material, Configuration, End User, and Region Regions covered North America, Europe, Asia-Pacific, and the Rest of the World (RoW) Countries covered The U.S., Canada, Mexico, Germany, France, Italy, Rest of Europe, China, Japan, South Korea, Rest of Asia-Pacific, South America, and the Middle East and Africa Market drivers • Adverse health and ecological impacts of lead-based piezoelectric materials. • Favorable regulatory environment. • Increasing applications for lead-free piezoelectric ceramics. Interesting facts: At present, the production of lead-free piezoelectric ceramics is more complex, expensive, and energy-intensive than PZT because of the small quantities involved. Lead-free piezoelectric ceramics producers also face certain challenges, including higher cost of raw materials, more complex processing, delicate and irreproducible synthesis, and physical limitations of the lead-free composition. However, they are continuously expanding their production and development capabilities to cater to growing demand and customer requirements. In wearable applications, self-powered biocompatible electronic devices that monitor critical physiological signals of the human body are in high demand. Lead-free piezoelectric ceramics are non-toxic and can be effectively utilized as they are biocompatible and have high sensing capabilities. Emerging startups: Ionix AT: Ionix develops a wide range of proprietary high-performance piezoelectric materials that can function in extreme environments. It supplies sensors, transducers, and actuators that address market needs for high-performance applications. The report addresses the following questions: 1. What are the projected market size and growth rate? The estimated market size of the lead-free piezoelectric ceramics market is $549.8 million by the end of 2030. The CAGR is 12.3%. 2. Which factors are driving the growth of the market? Key market drivers include: Adverse health and ecological impact of lead-based piezoelectric materials. Favorable regulatory environment. Increasing applications of lead-free piezoelectric ceramics. 3. What are the challenges and opportunities of the market? Challenges include- Raw material extraction may lead to environmental risks. Performance constraints. - Opportunities include- Development of nano-piezoelectric ceramics. Applications within wearable technology. 4. Which market segments are covered in the report? Material, configuration, end-user, and region. 5. Which material will be dominant through 2030? The potassium sodium niobate segment will continue to dominate the market through 2030. 6. Which region has the largest market share? Asia-Pacific dominates the global market for lead-free piezoelectric ceramics. China continues to drive the demand for lead-free piezoelectric ceramics, led by its robust manufacturing industry, mainly in automotive, electronics, and medical. Market leaders include: CERAMTEC GMBH CTS CORP. FUJI CERAMICS CORP. HONDA ELECTRONICS CO. LTD. IONIX AT KEMET CORP. KYOCERA CORP. NITERRA CO. LTD. NINGBO FBELE ELECTRONICS CO. LTD. PI CERAMIC GMBH PZT ELECTRONIC CERAMIC CO., LTD. SEIKO EPSON CORP. SUMITOMO CHEMICAL CO., LTD. TANIOBIS ZIBO YUHAI ELECTRONIC CERAMIC CO., LTD. Related reports: Global Markets for Automotive Sensor Technologies: The report analyzes the global automotive sensor market, focusing on sensor types, applications, vehicle categories, propulsion technologies, sales channels, and regional trends. It excludes two-wheelers and agricultural/industrial vehicles. Key segments include passenger and commercial vehicles, ICE and alternative fuel technologies, and OEM vs. aftermarket sales. The study highlights sensor deployment in areas like powertrain, safety, and autonomous systems. Purchase a copy of the report direct from BCC Research. For further information on any of these reports or to make a purchase, contact info@ About BCC Research BCC Research market research reports provide objective, unbiased measurement and assessment of market opportunities. Our experienced industry analysts' goal is to help you make informed business decisions free of noise and hype. Contact UsCorporate HQ: 50 Milk St., Ste. 16, Boston, MA 02109, USAEmail: info@ +1 781-489-7301For media inquiries, email press@ or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. Logo: View original content to download multimedia: SOURCE BCC Research LLC Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
29 minutes ago
- Business Wire
ClearStrand-ASD, First-of-Its-Kind Autism Screening Tool, Now Available in Japan
NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)-- LinusBio, a leader in precision exposome medicine, announced today that ClearStrand-ASD™, its biochemical autism screening test, is now available to patients and providers in Japan for research use through its partnership with YAC Bio. This milestone marks LinusBio's first international expansion and represents a significant step in the company's mission to enable earlier identification of autism spectrum disorder (ASD) globally. Today marks a transformational moment in our mission to make early autism screening accessible worldwide. Share ClearStrand-ASD requires only a strand of hair to detect molecular signatures associated with autism spectrum disorder. This innovative, non-invasive approach provides healthcare providers with an objective screening method that can help identify ASD risk as early as one month of age, allowing families to pursue intervention during the most crucial period of early development. "Today marks a transformational moment in our mission to make early autism screening accessible worldwide," said Dr. Manish Arora, Founder and CEO of LinusBio. "Japan represents our first step beyond U.S. borders, and we chose this market because of its sophisticated healthcare infrastructure and commitment to pediatric developmental care. Japanese families dealing with autism concerns will now have access to the same cutting-edge screening technology that has already helped multiple American families get answers earlier than ever before." The Japanese launch builds on ClearStrand-ASD's successful rollout across the United States, where it is now available in 49 states. YAC Bio will partner with hospital systems in Japan to facilitate the implementation of this first-of-its-kind biomarker test for autism. LinusBio's expansion into Japan is facilitated through its existing partnership with YAC Bio (part of Y.A.C. Holdings), the Japanese multinational that invested over 1 billion yen in the company. Beyond providing market access, Y.A.C. Holdings contributes manufacturing expertise and automation capabilities that support LinusBio's scaling efforts globally. "By combining the world's only hair-cutting robotics technology with the innovative hair exposome analysis developed by LinusBio in the United States, we have contributed to the development of the world's first biomarker screening test for autism spectrum disorder. Following its launch in the U.S., we are now offering this test in Japan through our group company, YAC Bio," said Takefumi Momose, President and CEO, Y.A.C. Holdings Co., Ltd. "We sincerely hope that this test will support individuals, families, and communities in Japan who are concerned about autism." The Japan availability of ClearStrand-ASD represents the first phase of LinusBio's international expansion strategy, with the company evaluating additional markets where ClearStrand-ASD could address unmet needs in early autism detection. About ClearStrand-ASD ClearStrand-ASD is a biochemical test intended to help health care providers rule out autism spectrum disorder (ASD) in children 1 to 48 months. The test analyzes a strand of hair to map the dynamic patterns of an individual's unique biological responses at a molecular level to environmental exposures over time and uses an algorithm to assess the likelihood of autism. It is not a genetic test and must be ordered by a licensed health care provider (Rx only). ClearStrand-ASD is performed at LinusBio's CLIA-certified laboratory (CLIA #31d2307499). For more information visit: About LinusBio LinusBio (Linus Biotechnology Inc.) is a patient-centric, breakthrough science precision exposome medicine company headquartered in New Jersey. The Company's program pipeline comprises precision exposome medicine biomarkers and target discovery across disease domains for which historically no molecular endpoints have been available in medical practice or for clinical trials, including CNS (autism spectrum disorder, amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology. LinusBio is actively exploring additional international partnerships to expand global access to its innovative diagnostic solutions. For more information, visit About Y.A.C. Holdings Y.A.C. Holdings is a Japan-based company specializing in developing, designing, and manufacturing mechatronics-related products. The company collaborates with LinusBio on hardware innovations to scale testing capacity, driving breakthroughs in robotics and laboratory automation.
Business Wire
29 minutes ago
- Business Wire
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse
NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Evolysse ™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume. 'This submission represents an important milestone in expanding our Evolysse ™ collection of injectable HA gels,' said Dr. Rui Avelar, MD, Chief Medical Officer and Head of R&D. 'Sculpt is our most structured product, manufactured using a novel technology and designed to address mid-face volume loss, a high-value segment in facial aesthetics.' Evolus anticipates that the FDA's review will follow the standard PMA process, with approval expected in the second half of 2026. The submission underscores Evolus' commitment to bringing its collection of injectable hyaluronic acid gel products to market and its readiness to meet rigorous regulatory requirements. In support of the PMA application, a U.S. pivotal study which evaluated the safety and effectiveness of the product in a multicenter, double-blinded, controlled, non-inferiority designed trial was conducted. Patients were followed for 24 months from initial treatment. A total of 304 patients were enrolled and randomized to receive Evolysse ™ Sculpt or Restylane ® -Lyft. The Evolysse ™ Sculpt injectable HA gel product is expected to be the flagship brand in the Evolysse ™ collection. Designed by Symatese using innovative Cold-X ™ technology, which helps preserve the natural structure of the HA molecule for long-lasting, natural-looking results, Sculpt will enter the highest value segment for today's dermal filler market and be among the few products currently indicated for the mid-face area. About Evolus, Inc. Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau ® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse ™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at and follow us on LinkedIn, X, Instagram or Facebook. Forward-Looking Statements This press release contains forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, including statements about future events, our business, financial condition, results of operations and prospects, our industry and the regulatory environment in which we operate. Any statements contained herein that are not statements of historical or current facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'will,' 'would' or the negative of those terms, or other comparable terms intended to identify statements about the future. The company's forward-looking statements include, but are not limited to, statements related to anticipated product launches and the timing of regulatory submissions and approvals. The forward-looking statements included herein are based on our current expectations, assumptions, estimates and projections, which we believe to be reasonable, and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by the forward-looking statements. These risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond our control, include, but are not limited to, uncertainties associated with our ability to comply with the terms and conditions in the Medytox Settlement Agreements, our ability to fund our future operations or obtain financing to fund our operations, unfavorable global economic conditions and the impact on consumer discretionary spending, uncertainties related to customer and consumer adoption of Jeuveau ® and Evolysse ™, the efficiency and operability of our digital platform, competition and market dynamics, our ability to successfully launch and commercialize our products in new markets, including the Evolysse ™ dermal filler product line in the U.S., our ability to maintain regulatory approvals of Jeuveau ® or obtain regulatory approvals for new product candidates or indications, our reliance on Symatese to achieve regulatory approval for the Evolysse ™ dermal filler product line in the U.S., and other risks described in our filings with the Securities and Exchange Commission, including in the section entitled 'Risk Factors' in our Annual Report on Form 10-K and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the Securities and Exchange Commission on August 5, 2025. These filings can be accessed online at Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, we undertake no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events. If we do update or revise one or more of these statements, investors and others should not conclude that we will make additional updates or corrections. Jeuveau ® and Nuceiva ®, are registered trademarks and Evolysse ™ is a trademark of Evolus, Inc. Hi-Pure ™ is a trademark of Daewoong Pharmaceutical Co, Ltd. Cold-X ™ and Estyme ® are trademarks of Symatese Group and Symatese Aesthetics S.A.S. Restylane ® is a trademark of Galderma S.A.
